Our goal is to be a world leader in the treatment of mitochondrial degenerative diseases. We devote our entire efforts to diseases such a Parkinson’s, Alzheimer’s, Lou Gehrig’s, diabetes, cardiac ischemia, stroke, cardiomyopathy, peripheral neuropathy, optic neuropathy, glaucoma, deafness and a range of mitochondrial orphan diseases.

Moving from palliative medicine to treating cause and controlling progression opens doors to better health and wellbeing.

We hope and believe that aside from alleviating enormous human suffering such medicines can reduce the overall spiral of healthcare costs, enabling broader and more stabilizing social and economic progress in developed and developing societies.

​

In the developed world a majority of healthcare cost is expended on treating degenerative diseases of aging, which is comprised of three major classes of disease, those being mitochondrial degenerative diseases, autoimmune diseases and cancers. Until a century ago the over sixty five years age group amounted to less than three percent of the world’s population, today they amount to about fifteen percent of the population in the developed world and they will increase to about twenty five percent of the population by mid century.